Low iodine diet does not improve the efficacy of radioiodine for the treatment of Graves’ disease
| Autor: | Teresa S. Kasamatsu, Magnus R. Dias-da-Silva, Ilda S. Kunii, Rosalia P. Padovani, Vanessa A. Santarosa, José Gilberto H. Vieira, Gilberto K. Furuzawa, Marilia M. S. Marone, Rui M. B. Maciel, Mario Luiz Vieira Castiglioni, Lia B. Fiorin, João Roberto Maciel Martins, Denise Orlandi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Endocrinology Diabetes and Metabolism Graves' disease chemistry.chemical_element Nutritional Status lcsh:Medicine Iodine Gastroenterology lcsh:Diseases of the endocrine glands. Clinical endocrinology Iodine Radioisotopes Young Adult Internal medicine medicine Humans Young adult Thyroid cancer Aged Food Formulated iodine nutritional status lcsh:RC648-665 Benign disease business.industry Thyroid disease lcsh:R Middle Aged medicine.disease Combined Modality Therapy Graves Disease Urinary iodine Surgery Trace Elements radioiodine Treatment Outcome chemistry Female business Graves’ disease Follow-Up Studies |
| Zdroj: | Archives of Endocrinology and Metabolism v.59 n.6 2015 Arquivos de Endocrinologia e Metabolismo Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) instacron:SBEM Archives of Endocrinology and Metabolism, Vol 59, Iss 6, Pp 501-506 (2015) Archives of Endocrinology and Metabolism, Volume: 59, Issue: 6, Pages: 501-506, Published: 25 SEP 2015 |
| Popis: | Objective Consuming a low-iodine diet (LID) is a widely accepted practice before administering radioiodine (131I) to evaluate and to treat thyroid disease. Although this procedure is well established for the management of patients with differentiated thyroid cancer, its use in patients with benign disease is unclear. So, we aimed to evaluate the influence of a LID on the outcome in patients with Graves’ disease (GD) treated with131I. Subjects and methods We evaluated 67 patients with GD who were divided into 2 groups: one group (n = 31) consumed a LID for 1-2 weeks, and the second group (n = 36) was instructed to maintain a regular diet (RD). Results The LID group experienced a 23% decrease in urinary iodine after 1 week on the diet and a significant 42% decrease after 2 weeks on the diet. The majority (53%) of the patients in the LID group had urinary iodine levels that were consistent with deficient iodine intake. However, there was no difference in the rate of hyperthyroidism’s cure between the LID and the RD groups 6 months after 131I therapy. Furthermore, the therapeutic efficacy did not differ in patients with varying degrees of sufficient iodine intake (corresponding urinary iodine levels: < 10 μg/dL is deficient; 10-29.9 μg/dL is sufficient; and > 30 μg/dL is excessive). Conclusion In the present study, we demonstrated that although a LID decreased urinary iodine levels, those levels corresponding with sufficient or a mild excess in iodine intake did not compromise the therapeutic efficacy of131I for the treatment of GD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|